Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Sep 12, 2022 12:46pm
153 Views
Post# 34956975

RE:RE:RE:RE:RE:RE:What did we learn here?

RE:RE:RE:RE:RE:RE:What did we learn here?Tumor growth inhibition, in other words, slowing down growth speed, is not even stable disease on an animal model, so not close to tumor shrinkage. I understand that these CSCs are very resistant, but this is relatively minor result. It adds a thin layer of knowledge to the whole thing on animal models and genetically homogenous tumors, but it really does not mean much for real human patients.

For me the main thing I take from this PR, is that they were willing to publish it at this stage. Maybe I don't understand how it works in reality, but it seems to me that I would not publish positive results on animals if I would not already have some efficacy data in the phase Ib. If they have these efficacy signs in phase Ib, then it makes a lot of sense to publish this press release today. It's a way to send a signal that everything is on track. That's the way I see it, but again, it's only me.
<< Previous
Bullboard Posts
Next >>